EPM Scientific’s Post

At the 2024 #DPHARM Conference, we interviewed Peyton Howell, CEO of Parexel. Key insights emerged on industry trends, challenges, and future strategies. Key Takeaways: • 100 Days as CEO: Howell’s early focus has been engaging with customers and employees to identify opportunities to enhance Parexel’s operations. • Industry Trends: AI and machine learning, patient-focused trial design, and decentralized clinical trials drive innovation in clinical research. • Patient Advocacy: A powerful patient keynote reminded the industry to prioritize patient awareness and involvement in trial design. • Adapting Strategies: Howell emphasized reducing trial complexity, expanding global research, and finding cost-efficient ways to operate in high-cost markets like the U.S. • Talent Development: Growing talent and maintaining a patient-centric focus are crucial for future success in clinical research. #ClinicalResearch #AI #PatientCentricity #DecentralizedTrials #DPHARM2024 #Parexel Rosanne Lucca Magariello Alyssa Salela

Nanogenics' own Suzy Dilly is joining the #Pharmaintegrates event hosted by Life Science Integrates next month! Discussing the topic "Patients are a Virtue", the panel will consider the impact of patient involvement in drug development. Follow the link for further details! #networking #biotech #innovation

Have you secured your free place at a PHUSE Single Day Event in May? If you're based in Boston or the Netherlands then don't miss out on this opportunity as both the events are focused on AI and it's impact on our industry. Stay ahead of the curve and pick up the actionable takeaways you need to implement this technology into your daily practices.  ↳Boston, MA | Tuesday 7 May Theme: AI and the Impact on our Daily Activities in the Pharmaceutical Industry View Agenda & Register: https://lnkd.in/eW5g3Tix *1 WEEK LEFT TO REGISTER!*  ↳Utrecht, the Netherlands | Thursday 30 May Theme: AI and ML in Life Sciences and Healthcare: Enhancing Clinical Research & Data Analysis View Agenda & Register: https://lnkd.in/ejZf67hW These one-day global events are a perfect way to get a quick hit of valuable information on a particular hot topic within the industry. So, whether you're a dedicated PHUSE Single Day Event attendee or have yet to join us, we would love to welcome you! #PHUSE

Today, on International Clinical Trials Day, I reflect on my life sciences career journey that began at Quintiles (now IQVIA). It was at Quintiles that I first witnessed the incredible impact of clinical trials in advancing human health. From those early days, I learned the importance of dedication, precision, and collaboration in bringing new treatments to the patients who need them. With the advent of AI in clinical research, we're entering a new era of possibilities. AI is revolutionizing how we design, conduct, and analyze trials, making the process more efficient and uncovering insights that were previously out of reach. This technology enhances our ability to accelerate discoveries and bring life-saving treatments to patients faster. As we honor the contributions of everyone involved in clinical research – from scientists, data scientists, biostatisticians and researchers to patients – let's remember that our work is not just about data and protocols. It's about the lives we touch and the futures we help shape. Here's to continued progress, innovation, and the relentless pursuit of a healthier world. Happy Clinical Trials Day! #ICTD24 #MedicalInnovation #ClinicalResearch #AIinHealthcare

Cristy Patterson, our Senior Director of Life Sciences Partnerships, attended #CRAACO2024 and #DPHARM2024 earlier this week in Philadelphia. Here are some of her key takeaways from the conferences. 🩺Supporting research-naive investigators — To increase the diversity of trial participants, we need to include more investigators who haven’t previously conducted research, but sponsors have specific criteria and infrastructure requirements that can make it harder for interested clinicians to get started. 🔍 Sourcing eligible patients – Patient identification continues to be a challenge, and while there is a huge range of technology solutions that can support the process, they are not one-size-fits all. 🤝Identifying strong partners — The right partnerships continue to hinge on building trusted relationships, and evaluating who might be the right partners is challenging, even for large organizations. 🔢Leading with data — Sponsors are increasingly using AI to analyze past performance data and incorporate predictive elements to determine which sites are likely to be strong performers for research. However, we need to be aware of bias, whether human-based or pre-existing, in the data used to build the models.

The rapidly evolving pharma and medtech services space is attractive to investors, but successful investors must consider key factors currently impacting the space, including the use of AI and data, the impact of government legislation and ensuring diverse patient enrollment in clinical trials. Learn more: https://lnkd.in/ep2Yqzr2

Hi, LinkedIn community! I'm sorry for the delay in publication. I've been busy working on Signify Research's most recent report, "Vendor Opportunities and Strategies for EMR and Digital Health Vendors in Generative AI." The link to my Insight related to this report can be found here: https://lnkd.in/d4E-b6Mu If you'd like to learn more about the report, please don't hesitate to reach out to me directly. Now, onto the newsletter - I've curated a list of the most interesting developments in June for health tech companies in generative AI. You'll notice a significant number of pharma and life sciences developments, as well as numerous partnership announcements. This second highlight is explored in depth in my newsletter, which you can access here: https://lnkd.in/dZeFFbVr

Tempus: Shaping Healthcare's Future" Healthcare is in the midst of a significant transformation, and Tempus stands at the forefront of this movement. They have made remarkable efforts underway to shape the future of healthcare through data-driven precision medicine. ⭐ Problem-Solving: Amidst the abundance of medical data, the challenge lies in extracting meaningful insights. Tempus tackles this challenge head-on, deciphering complex datasets to drive improved patient outcomes. ⭐ Innovative Solutions: Tempus relies on advanced technology and a dedication to innovation. Their use of AI and machine learning creates platforms that not only analyze data but also offer actionable recommendations, revolutionizing healthcare delivery. ⭐ Competitive Advantage: Tempus distinguishes itself through an unwavering commitment to pushing boundaries. By continuously refining their solutions and staying ahead of industry trends, they maintain a competitive edge as leaders in precision medicine. ⭐ Overcoming Challenges: Despite facing obstacles such as regulatory compliance and data privacy concerns, Tempus perseveres through collaboration, resilience, and an unyielding pursuit of excellence, emerging stronger and catalyzing meaningful change in healthcare. Team members:Aashi Jain Vishesh Jain Mahek Bhatt Riddhi Thakkar Diya Jain #PrecisionMedicine #HealthcareInnovation #DataDrivenCare #TempusLeadership"

Recognizing the limited development of traditional #clinicaltrials, the EU has recently funded five projects under the Horizon Europe program to enhance regulatory decision-making and health technology assessments (HTA) using #RWE. These projects, part of the MetReal Cluster, aim to optimize data-driven methodologies across various health sectors, including drug development, diabetes care, medical device software, and cancer therapy evaluation.   These initiatives seek to improve #healthcare outcomes through more informed, effective, and personalized decisions by fostering collaboration across stakeholders and harnessing innovative technologies like #AI.   Read the complete development here: https://lnkd.in/eQDmskuG   Follow Actu-Real for more insightful posts on healthcare, AI, machine learning, health economics, outcomes research, and real-world data.   #IntheNews #ActuReal #Healthcare #RealWorldEvidence

Friday Fuel 💜 Exciting developments in the clinical trials space have marked the beginning of the year, showcasing the rapid pace of technological advancements. Three standout themes from the last three months and upcoming trends in Q2 are worth reflecting on: 🔹 AI's Growing Role in Enhancing Patient Experience 🔹 Advancements in Inclusivity, Diversity, and Patient-Centricity 🔹 FDA's Ongoing Efforts in Diversity Guidance Development Power(imagine Airbnb but for clinical trials), is revolutionizing how patients access cutting-edge medical research. By facilitating patient-research team connections, Power not only offers hope to patients but also provides sponsors with an efficient pathway to engage with patients online. Access the full report here: https://lnkd.in/gChZdZAQ